Results 41 to 50 of about 25,722,272 (279)
Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis [PDF]
, 2023 As a novel widely used drug, sodium-glucose co-transporter (SGLT) 2 inhibitor may lower blood glucose in type 2 diabetics through blocking SGLT2 to curtain glucose reabsorption in proximal renal tubular cells.
Xiao-qi Wang +5 more
core +1 more source
A case report of euglycemic ketoacidosis due to dapagliflozin treatment
Turkish Journal of Internal Medicine, 2021 Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu +4 more
doaj +1 more source
Acta Marisiensis - Seria MedicaSodium-glucose transporter 2 inhibitors have been identified as pleiotropic pharmacological agents with demonstrated efficacy in a wide range of pathologies.
Prația-Aron Diana-Ioana +2 more
doaj +1 more source
A cell-based fluorescent glucose transporter assay for SGLT2 inhibitor discovery
Acta Pharmaceutica Sinica B, 2013 The sodium/glucose cotransporter 2 (SGLT2) is responsible for the majority of glucose reabsorption in the kidney, and currently, SGLT2 inhibitors are considered as promising hypoglycemic agents for the treatment of type 2 diabetes mellitus.
Yi Huan +4 more
doaj +1 more source
Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report
BMC Pharmacology and Toxicology, 2020 Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit SGLT2, which is expressed in the proximal renal tubule, and thus reduce blood glucose levels by enabling the urinary excretion of excess glucose.
Miho Nakamura +4 more
doaj +1 more source
Discerning protein pools by selective staining with self‐labeling tags
FEBS Letters, EarlyView.Cell surface proteins have an intra‐ and extracellular pool. Combining genetic fusion to self‐labeling tags that can be addressed with small molecule fluorophores allows separating these pools. We highlight recent developments and techniques for state‐of‐the‐art interrogation of cell surface proteins in the complex tissue setting.
Kati Fischermanns, Johannes Broichhagen
wiley +1 more source
, 2021 Aims To examine the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure (HF), and to explore the subsets of patients who may have greater benefit from ...
Yueying Wang +8 more
core +1 more source
FEBS Letters, EarlyView.Animals must match their growth rate to available nutrients. We show that in Drosophila larvae, the nutrient‐sensing TOR kinase controls growth by regulating levels of TFAM, a key regulator of mitochondrial function, in the adipose tissue. When nutrients are abundant, high TOR activity suppresses TFAM, lowering mitochondrial bioenergetic activity and ...
Shrivani Sriskanthadevan‐Pirahas +4 more
wiley +1 more source
, 2021 Sodium glucose-linked transport protein 2 inhibitors are relatively novel drugs, used for the treatment of type 2 diabetes mellitus. Their use since Pharmaceutical Benefits Scheme approval in Australia has increased drastically, possibly due to the low ...
Nesbitt, A +4 more
core +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source